Results 21 to 30 of about 106,446 (312)

Relationship between antihypertensive medications and cognitive impairment: Part II. Review of Physiology and animal studies [PDF]

, 2016
Purpose of Review There is an established association between hypertension and increased risk of poor cognitive performance and dementia including Alzheimer’s disease; however, associations between antihypertensive medications (AHM) and dementia risk are
Carlson, MC, Peters, J, Peters, R, Schuchman, M, Yasar, S   +4 more
core   +1 more source

Neuroprotective Effects of Angiotensin Receptor Blockers [PDF]

American Journal of Hypertension, 2014
Angiotensin II receptor blockers (ARBs, collectively called sartans) are widely used compounds therapeutically effective in cardiovascular disorders, renal disease, the metabolic syndrome, and diabetes. It has been more recently recognized that ARBs are neuroprotective and have potential therapeutic use in many brain disorders.
Sonia, Villapol, Juan M, Saavedra
openaire   +2 more sources

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure with reduced ejection fraction (HFrEF). However, the effectiveness of sacubitril/valsartan in older patients hospitalized for HFrEF in real‐world US ...
Stephen J. Greene, Sujung Choi, Steven J. Lippmann, Robert J. Mentz, Melissa A. Greiner, N. Chantelle Hardy, Bradley G. Hammill, Nancy Luo, Marc D. Samsky, Paul A. Heidenreich, Warren K. Laskey, Clyde W. Yancy, Pamela N. Peterson, Lesley H. Curtis, Adrian F. Hernandez, Gregg C. Fonarow, Emily C. O'Brien   +16 more
doaj   +1 more source

Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study [PDF]

, 2017
Background: Angiotensin converting enzyme inhibitors (ACEIs) are recommended as first-line therapy in patients with heart failure with reduced ejection fraction (HFrEF). The comparative effectiveness of different ACEIs is not known. Methods and results:
Agewall, Stefan, Atar, Dan, Clark, Andrew L., Cleland, John G.F., Corletto, Anna, Frankenstein, Lutz, Fröhlich, Hanna, Goode, Kevin, Grundtvig, Morten, Henning, Felix, Hole, Torstein, Katus, Hugo A., Kazmi, Syed, Schellberg, Dieter, Täger, Tobias   +14 more
core   +1 more source

Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme [PDF]

, 2016
Aims We investigated the association between worsening renal function (WRF) that occurs during renin–angiotensin–aldosterone system inhibition initation and outcome in heart failure (HF) patients with preserved ejection fraction (HFPEF) and compared ...
Brenner, Clark, Damman, Damman, Damman, Hillege, Lesogor, Lewis, Lindenfeld, Massie, McAlister, McMurray, National Institute for Health and Clinical Excellence, Pfeffer, Rossignol, Rossignol, Rusinaru, Swedberg, Testani, Vardeny, Yancy, Yusuf   +21 more
core   +1 more source

Hypertension as a Risk Factor: Is It Different in Ischemic Stroke and Acute Myocardial Infarction Comparative Cross-Sectional Study?

International Journal of Hypertension, 2011
Objective. To assess differences in age of onset, hypertension duration, type of drug, treatment compliance, and salt-free diet compliance between patients with stroke and myocardial infarction. Patients and Methods.
Zaki Noah Hasan, Mousa Qasim Hussein, Ghazi Farhan Haji   +2 more
doaj   +1 more source

Effect of long-term therapy with AT1angiotensin II receptor blockers in combination with aldosterone receptor inhibitor on ischemic myocardial remodelling and chronic heart failure

Медицинский совет, 2014
The article presents the results of a 6-month long-term therapy with angiotensin II receptor blocker Valsacor and aldosterone receptor blocker Spironolactone in patients with chronic heart failure (CHF) against a background of ischemic and/or post ...
AT Teplyakov, EV Grakova, AV Andrianova, EY Pushnikova, NV Protopopova, RS Karpov   +5 more
doaj   +1 more source

Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes [PDF]

, 2017
Acknowledgements: The authors thank all participants who contributed to the study. Funding: CPACS-1 was funded by unrestricted educational grants from Guidant and Sanofi-Aventis, and grants from The Royal Australasian College of Physicians.
Gao, Runlin, Li, Min, Li, Shenshen, Li, Xian, Myint, Phyo Kyaw, Patel, Anushka, Sun, Yihong, Wu, Tao, Wu, Yangfeng, Xie, Gaoqiang, Yang, Xingzi   +10 more
core   +1 more source

Next generation multifunctional angiotensin receptor blockers [PDF]

Hypertension Research, 2009
Angiotensin receptor blockers (ARBs) are well-tolerated drugs that are known to be useful for inhibiting activity of the renin-angiotensin (RAS) system, treating hypertension and reducing the risk for cardiovascular disease. However, inhibition of the RAS does not control all pathophysiological mechanisms of hypertension or cardiovascular risk and many
Theodore W, Kurtz, Uwe, Klein
openaire   +2 more sources

Candesartan in nephrological practice

Počki, 2014
First-line drugs in the treatment of hypertension in patients with chronic kidney disease is an angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.
Ya.A. Dombrovskyi, D.D. Ivanov
doaj   +1 more source